April 20, 2021
More than 60 dogs now receiving LAVERDIA-CA1 as part of Anivive's compassionate use program
April 14, 2021
LA Zoo calls Anivive's CMO Dave Bruyette to perform an endoscopy on a beloved gibbon suffering from chronic intestinal disorder
April 2, 2021
LAVERDIA-CA1 inventory has arrived at Anivive's Long Beach warehouse.
(L to R) Dylan Balsz, Founder and CEO, Cody Arbuckle, Chief Technology Officer, and David Bruyette, Chief Medical Officer at Anivive in front of the inventory in the truck. When David and Cody joined the company, Anivive had not yet settled on developing LAVERDIA-CA1.
January 21, 2021
Anivive Announces FDA Conditional Approval of LAVERDIA™-CA1 (verdinexor) - the First and Only Oral Tablet to Treat Lymphoma in DogsView all press releases
April 12, 2021
Anivive sprints to market with pet chemotherapy
Anivive Lifesciences Inc. is taking its first pet-specific drug to market after 3.5 years and $5 million in research and development costs.
Orange County Business Journal
January 18, 2021
FDA endorses canine epilepsy and lymphoma drugs
Medications from Pegasus Laboratories and Anivive Lifesciences earned conditional approvals.
Today’s Veterinary BusinessRead More
August 31, 2020
Cats point the way to potential COVID-19 remedies
Anivive Lifesciences, is working on a COVID-19 antiviral drug that’s inspired by cats, and it has new preclinical research findings to back up the project.
June 9, 2019
A drugs life: How David Bruyette’s biotech startup is changing the way veterinary products come to market
Anivive Lifesciences starts with unmet therapeutic needs and employs high-tech research methods to identify compounds that could meet those needs.
Our financial statement audits have been performed to Public Company Accounting Oversight Board (PCAOB) standards. These standards set the independence and audit requirements for the auditors, the level of financial reporting by the Company and are required for publicly held companies.
Audited Financial Statements